Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Takeda Pharma-Photo by Veroniksha via Shutterstock

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Under the terms of the agreement, Nabla Bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.